|MDACC Study No:||2012-0626 (clinicaltrials.gov NCT No: NCT01644253)|
|Title:||A Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab or in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia|
|Principal Investigator:||Susan O'Brien|
|Treatment Agent:||Rituximab; TRU-016|
|Study Description:||The goal of this clinical research study is to learn more about how safe the |
drug TRU-016 is to give in combination with rituximab or obinutuzumab to
patients with CLL. The potential effects of this drug will also be studied.
TRU-016 is a protein made to act like an antibody that is designed to find and
destroy certain cells. TRU-016 works against a certain kind of white blood
cell (a “B cell”). This means that it may decrease the number of B cells in
your blood. Decreasing the number of these B cells may slow the growth of CLL.
Rituximab and obinutuzumab are also antibodies that are designed to work
against B cells and decrease the number of B cells in your blood, which may
slow the growth of CLL.